Headquartered in Waltham, MA Fiscal year ends December NASDAQ: AKBA akebia.com
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on improving the lives of people impacted by kidney disease. The company markets Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia due to chronic kidney disease in adults on dialysis, now approved in 37 countries. Akebia also markets Auryxia (ferric citrate), which faces increasing generic competition. Beyond its commercial portfolio, Akebia is advancing a rare kidney disease pipeline that includes ebribafusp, a next-generation complement inhibitor being studied in IgA nephropathy, lupus nephritis, and C3 glomerulopathy, and praliciguat, currently in a Phase 2 trial for focal segmental glomerulosclerosis (FSGS). The company's Vafseo intellectual property portfolio includes 14 Orange Book-listed patents with expiration dates extending to 2036. Updated
Thursday’s additional top analyst upgrades and downgrades included Advanced Micro Devices, Akebia Therapeutics, Dell Technologies, HP, Starwood Property Trust and State Street.
The Friday afternoon analyst calls were focused on Biogen, 3D Systems, Duke Energy, Ford, and more.
Friday's top analyst calls included Akebia Therapeutics, Broadcom, DocuSign, Lululemon Athletica, NextEra Energy, Overstock.com, Shopify and Wayfair.
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on improving the lives of people impacted by kidney disease.
The Wall Street consensus 12-month price target for AKBA is $3.92.
